SWOG clinical trial number
C9687
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Cancer.
Closed
Phase
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Pts must have biopsy proven persistence or recurrence of prostate cancer with no evidence of metastatic disease at the time of biopsy. Pts must have a PS of 0-1. Pts must have been treated with >/= 60 cGy external beam RT or brachytherapy for clinical states T1-2, NX, M0 PC w/PSA < / = to 30 ng/ml prior to RT. It must be > / = 18 mos since last RT and > / = to 3 mos since last adj hormonal tx. Pts dx'ed w/another malignancy w/in previous 5 years (except for non-melanoma skin ca or Ta bladder ca) are not eligible. Pts must have a PSA of < / = 20 ng/ml obtained within 30 days prior to registration.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase